Streetbeat News

Price Targets

TVTX

Leerink Partners has maintained an 'Outperform' rating on Travere Therapeutics and raised the price target from $20 to $40, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:42 pm

DAL

JP Morgan analyst Jamie Baker maintains an Overweight rating on Delta Air Lines and raises the price target from $68 to $80.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:36 pm

MANH

Truist Securities has maintained a Buy rating on Manhattan Associates and raised the price target from $275 to $310.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:34 pm

DE

JP Morgan analyst Tami Zakaria maintains a Neutral rating on Deere (NYSE:DE) but raises the price target from $360 to $420.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:33 pm

INSM

Truist Securities has maintained a Buy rating on Insmed and raised its price target from $85 to $100, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:33 pm

CMI

JP Morgan analyst Tami Zakaria maintains an Underweight rating on Cummins (NYSE:CMI) but raises the price target from $285 to $340.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:31 pm

HUM

Truist Securities has maintained a Hold rating on Humana (NYSE:HUM) but has significantly lowered its price target from $400 to $260.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:30 pm

CVS

Truist Securities has maintained a Buy rating on CVS Health and increased the price target from $66 to $76, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:29 pm

CL

JP Morgan analyst Andrea Teixeira maintains an Overweight rating on Colgate-Palmolive and raises the price target from $113 to $114.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:27 pm

WYNN

Susquehanna analyst Rachael Rothman maintains a Positive rating on Wynn Resorts and raises the price target from $92 to $122.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:27 pm